Cellsway

The company develops a microfluidic liquid biopsy platform for cancer monitoring through the enrichment and analysis of Circulating Tumor Cells (CTCs) from blood samples. Its product suite includes an automated enrichment device, patented microfluidic chips, and specialized immunofluorescence test panels for identifying biomarkers such as ER, PR, HER2, and PD-L1. These tools are designed for use in clinical laboratories and research settings to facilitate minimally invasive patient profiling and cancer management.